Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 5:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 434 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Glioblastoma, Adult Clear all
Completed Phase 1Phase 2 Interventional Results available

A Study of BBI608 in Combination With Temozolomide in Adult Patients With Recurrent or Progressed Glioblastoma

NCT02315534
View directory record Official record
Conditions
Glioblastoma
Interventions
BBI608, Temozolomide
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 14, 2023 · Synced Sep 17, 2026, 5:15 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Laser Interstitial Thermotherapy (LITT) Combined With Checkpoint Inhibitor for Recurrent GBM (RGBM)

NCT03277638
View directory record Official record
Conditions
Glioblastoma, Adult
Interventions
Pembrolizumab at 7 days prior, Pembrolizumab at 14 days post, Pembrolizumab at 35 days post, Laser Interstitial Thermotherapy
Drug · Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Sep 17, 2026, 5:15 AM EDT
Active, not recruiting Phase 3 Interventional

A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma

NCT06388733
View directory record Official record
Conditions
Glioblastoma, GBM, Brain Neoplasms, Adult, Malignant, Brain Tumor
Interventions
Niraparib, Temozolomide
Drug
Lead sponsor
Ivy Brain Tumor Center
Other
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
32
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 1Phase 2 Interventional

Procarbazine in Treating Patients With Recurrent Brain Tumor

NCT00004004
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
procarbazine hydrochloride
Drug
Lead sponsor
New Approaches to Brain Tumor Therapy Consortium
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
10
States / cities
Birmingham, Alabama • Tampa, Florida • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 1 Interventional

Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to Treatment

NCT00544284
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Lymphoma, Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
bortezomib, temozolomide, pharmacological study
Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
2
States / cities
Duarte, California • Pasadena, California
Source: ClinicalTrials.gov public record
Updated Feb 14, 2013 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 1 Interventional

Cediranib Maleate and Cilengitide in Treating Patients With Progressive or Recurrent Glioblastoma

NCT00979862
View directory record Official record
Conditions
Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Neoplasm
Interventions
Cediranib Maleate, Cilengitide, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
11
States / cities
Birmingham, Alabama • Atlanta, Georgia • Baltimore, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2015 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 1 Interventional

Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Melanoma or Brain Tumors

NCT00002754
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Melanoma (Skin), Metastatic Cancer
Interventions
monoclonal antibody Me1-14 F(ab')2
Biological
Lead sponsor
Duke University
Other
Eligibility
3 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2001
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 19, 2013 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 2 Interventional Results available

Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma

NCT01730950
View directory record Official record
Conditions
Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
Interventions
bevacizumab, radiation therapy
Biological · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
31
States / cities
Birmingham, Alabama • Phoenix, Arizona • Walnut Creek, California + 26 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2022 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 2 Interventional Results available

Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

NCT00643097
View directory record Official record
Conditions
Malignant Neoplasms of Brain
Interventions
PEP-3 vaccine, sargramostim, Temozolomide
Biological · Drug
Lead sponsor
John Sampson
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
2
States / cities
Durham, North Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 31, 2017 · Synced Sep 17, 2026, 5:15 AM EDT
Completed No phase listed Observational

Risk Factors for Developing a Blood Clot in Patients Who Are Undergoing Cancer Treatment for Newly Diagnosed Gliomas

NCT00253669
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Thromboembolism
Interventions
laboratory biomarker analysis, physiologic testing, management of therapy complications
Other · Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
9
States / cities
Birmingham, Alabama • Tampa, Florida • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2018 · Synced Sep 17, 2026, 5:15 AM EDT
Completed No phase listed Observational

Genetic Study in Patients Receiving Treatment for Hodgkin's Disease or Childhood Brain Tumor

NCT00006342
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Lymphoma
Interventions
chromosomal translocation analysis, gene rearrangement analysis, mutation analysis
Genetic
Lead sponsor
Duke University
Other
Eligibility
Not listed
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2001
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 14, 2015 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 1Phase 2 Interventional Results available

FR901228 in Treating Patients With Recurrent High-Grade Gliomas

NCT00085540
View directory record Official record
Conditions
Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
Interventions
depsipeptide
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
8
States / cities
Los Angeles, California • San Francisco, California • Bethesda, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 1, 2017 · Synced Sep 17, 2026, 5:15 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma

NCT00761280
View directory record Official record
Conditions
Anaplastic Astrocytoma, Glioblastoma
Interventions
trabedersen, temozolomide, Drug delivery system for administration of AP 12009, Placement of Drug Delivery System, carmustine, lomustine
Drug · Device · Procedure
Lead sponsor
Isarna Therapeutics GmbH
Industry
Eligibility
18 Years to 70 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
3
States / cities
Edison, New Jersey • Mineola, New York • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Nov 13, 2014 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Tandutinib in Treating Patients With Recurrent or Progressive Glioblastoma

NCT00379080
View directory record Official record
Conditions
Adult Brain Tumor, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
Interventions
conventional surgery, tandutinib, pharmacological study, Tissue samples
Procedure · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
9
States / cities
Birmingham, Alabama • Tampa, Florida • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2017 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 1 Interventional

Gene Therapy in Treating Patients With Primary Brain Tumors

NCT00002824
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
gene therapy, chemotherapy, ganciclovir, conventional surgery
Biological · Drug · Procedure
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1996
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 12, 2019 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 2 Interventional Results available

Erlotinib and Sorafenib in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme

NCT00445588
View directory record Official record
Conditions
Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
Interventions
erlotinib hydrochloride, sorafenib tosylate, pharmacological study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
9
States / cities
Birmingham, Alabama • Tampa, Florida • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2016 · Synced Sep 17, 2026, 5:15 AM EDT
Recruiting No phase listed Observational

The RESBIOP-study: Resection Versus Biopsy in High-grade Glioma Patients (ENCRAM 2202)

NCT06146725
View directory record Official record
Conditions
Glioblastoma, Glioblastoma, IDH-wildtype, Glioblastoma Multiforme, Glioblastoma Multiforme, Adult, Glioblastoma Multiforme of Brain
Interventions
Tumor resection, Tumor biopsy
Procedure
Lead sponsor
Jasper Gerritsen
Other
Eligibility
18 Years to 90 Years
Enrollment
564 participants
Timeline
2023 – 2029
U.S. locations
2
States / cities
San Francisco, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 26, 2023 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 2 Interventional

Thalidomide and Procarbazine in Treating Patients With Recurrent or Progressive Malignant Glioma

NCT00079092
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
procarbazine hydrochloride, thalidomide
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 120 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
5
States / cities
Decatur, Illinois • Goldsboro, North Carolina • Winston-Salem, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2021 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 1 Interventional

Atrasentan in Treating Patients With Progressive or Recurrent Malignant Glioma

NCT00017264
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
atrasentan hydrochloride
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
10
States / cities
Birmingham, Alabama • Tampa, Florida • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2009 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 1 Interventional Results available

Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With Recurrent High Grade Gliomas

NCT02186509
View directory record Official record
Conditions
Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Anaplastic Oligodendroglioma, Adult Brain Stem Glioma, Adult Diffuse Astrocytoma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Mixed Glioma, Adult Oligodendroglioma, Adult Pilocytic Astrocytoma, Adult Pineal Gland Astrocytoma, Adult Subependymal Giant Cell Astrocytoma, Recurrent Adult Brain Tumor
Interventions
Hyperfractionated radiation therapy, Stereotactic radiosurgery, Alisertib, Quality-of-life assessment
Radiation · Drug · Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 1 Interventional

Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer

NCT00006368
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Breast Cancer, Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Lung Cancer, Lymphoma, Melanoma (Skin), Neoplastic Syndrome
Interventions
yttrium Y 90-edotreotide
Radiation
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2003
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 30, 2013 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 1 Interventional Results available

Temozolomide and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Anaplastic Astrocytoma

NCT00841555
View directory record Official record
Conditions
Glioblastoma Multiforme/Anaplastic Astrocytoma
Interventions
temozolomide, Hypofractionated radiation therapy, Intensity-modulated radiation therapy
Drug · Radiation
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 17, 2018 · Synced Sep 17, 2026, 5:15 AM EDT
Not listed Phase 1Phase 2 Interventional

Arsenic Trioxide, Temozolomide, and Radiation Therapy in Treating Patients With Malignant Glioma That Has Been Removed By Surgery

NCT00275067
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
arsenic trioxide, temozolomide, radiation therapy
Drug · Radiation
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2021
U.S. locations
3
States / cities
Chicago, Illinois • Naperville, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 24, 2020 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 1 Interventional

A Feasibility, Dose-Escalation Study Using Intracerebral Microdialysis to Assess the Neuropharmacodynamics of Temsirolimus in Patients With Primary or Metastatic Brain Tumors

NCT00784914
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Metastatic Cancer
Interventions
temsirolimus, pharmacological study, cytokine levels
Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Apr 16, 2018 · Synced Sep 17, 2026, 5:15 AM EDT